Tolgabide
Jump to navigation
Jump to search
Clinical data | |
---|---|
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
Chemical and physical data | |
Formula | C18H18Cl2N2O2 |
Molar mass | 365.25 g·mol−1 |
3D model (JSmol) | |
| |
|
Tolgabide (INN; development code SL-81.0142) is a drug which was patented by Synthélabo as an anticonvulsant but was never marketed.[1] It is an analogue of progabide and acts similarly to it as a prodrug of GABA, and therefore as an indirect agonist of the GABA receptors.[1][2]
See also
References
- ^ a b Triggle DJ (1996). Dictionary of Pharmacological Agents. Boca Raton: Chapman & Hall/CRC. ISBN 0-412-46630-9.
- ^ "The use of common stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances" (PDF). 2002.[dead link]
Categories:
- All articles with dead external links
- Articles with dead external links from December 2021
- Articles with short description
- Short description matches Wikidata
- Drugs not assigned an ATC code
- Drugs with non-standard legal status
- Chemical pages without DrugBank identifier
- Articles containing unverified chemical infoboxes
- Anticonvulsants
- Chloroarenes
- Phenols
- Carboxamides
- GABA analogues
- GABAA receptor agonists
- GABAA-rho receptor agonists
- GABAB receptor agonists
- Prodrugs
- Abandoned drugs